Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition

Drug News and Perspectives

Volumn 21, Issue 5, 2008, Pages 258-266

  Julius, Richard L ^a,b   Hawthorne, M Frederick ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CARBOXYLIC ACID 7 [3 FLUOROPHENYL] 1,7 DICARBA CLOSO DODECARBORANE; 2 ARYLBENZOXAZOLE DERIVATIVE; AMYLOID; BENZOXAZOLE DERIVATIVE; CARBORANE DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DIFLUNISAL; FLUFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANOBORON DERIVATIVE; PREALBUMIN; PROSTAGLANDIN SYNTHASE; THYROXINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DRUG STRUCTURE; ENZYME INHIBITION; FAMILIAL AMYLOID POLYNEUROPATHY; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STABILITY;

AMYLOID; AMYLOIDOSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; BORANES; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; HUMANS; PREALBUMIN; PROTEIN CONFORMATION; PROTEIN FOLDING; STRUCTURE-ACTIVITY RELATIONSHIP; THYROXINE;

EID: 51549110549     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.5.1219011     Document Type: Article

References (73)

1. Kyle, R.A. Amyloidosis: A convoluted story. Br J Haematol 2001, 114(3): 529-38.
2. Westermark, P., Benson, M.D., Buxbaum, J.N. et al. A primer of amyloid nomenclature. Amyloid 2007, 14(3): 179-83.
3. Selkoe, D.J. Folding proteins in fatal ways. Nature 2003, 426(6968): 900-4.
4. Meredith, S.C. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. Ann NY Acad Sci 2005, 1066: 181-221.
5. Sunde, M., Serpell, L.C., Bartlam, M., Fraser, P.E., Pepys, M.B. and Blake, C.C. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 1997, 273(3): 729-7396.
6. Sunde, M. and Blake, C.C. From the globular to the fibrous state: Protein structure and structural conversion in amyloid formation. Q Rev Biophys 1998, 31(1): 1-39.
7. Sawaya, M.R., Sambashivan, S., Nelson, R. et al. Atomic structures of amyloid cross-beta spines reveals steric zippers. Nature 2007, 447(7143): 453-7.
8. Conway, K.A., Harper, J.D. and Lansbury, Jr. P.T. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39: 2522-63
9. Fandrich, M., Fletcher, M.A. and Dobson, C.M. Amyloid fibrils from muscle myoglobin. Nature 2001, 410(6825): 165-6.
10. Dobson, C.M. The structural basis of protein folding and its links with human disease. Phil Trans R Soc Lond B 2001, 356: 133-45.
11. Bucciantini, M., Giannoni, E., Chiti, F. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416(6880): 507-11.
12. Stefani, M. and Dobson, C.M. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J Mol Med 2002, 81(11): 678-99.
13. Lambert, M.P., Barlow, A.K., Chromy, B.A. et al. Diffusible, nonfibrillar ligands derived from A-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998, 95(11): 6448-53.
14. Kirkitadze, M.D., Bitan, G. and Teplow, D.B. Paradigm shifts in Alzheimer's Disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J Neurosci Res 2002, 69(5): 567-77.
15. Reixach, N., Deechongkit, S., Jiang, X., Kelly, J.W. and Buxbaum, J.N. Tissue damage in the amyloidoses: Transthyretin monomers and non-native oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 2004, 101(9): 2817-22.
16. Cohen, F.E. and Kelly, J.W. Therapeutic approaches to protein-misfolding diseases. Nature 2003, 426(6968): 905-9.
17. Blake, C.C., Geisow, M.J., Swan, I.D.A., Rerat, C. and Rerat, B. Structure of human plasma prealbumin at 2.5 Å resolution: A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol 1974, 88(1): 1-12.
18. Blake, C.C., Geisow, M.J., Oatley, S.J., Rerat, B. and Rerat, C. Structure prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J Mol Biol 1978, 121(3): 339-56.
19. Schreiber, G. and Richardson, S.J. The evolution of gene expression, structure and function of transthyretin. Comp Biochem Physiol B Biochem Mol Biol 1997, 116(2): 137-60.
20. Robbins, J. Thyroid hormone transport proteins and the physiology of hormone binding. In: The Thyroid, L.E. Braverman, R.D. Utiger (Eds.). Lippincott Williams & Wilkins: Philadelphia 2000, 105-20.
21. Blay, P., Nilsson, C., Owman, C., Aldred, A. and Screiber, G. Transthyretin expression in the rat brain: effect of thyroid functional state and role in thyroxine transport. Brain Res 1993, 632(1-2): 114-20.
22. Naylor, H.M. and Newcomer, M.E. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 1999, 38(9): 2647-53.
23. 4-bound letramers of TTR. Acta Crystallogr D Biol Crystallogr 2001, 57(Pt. 7): 957-67.
24. Ferguson, R.N., Edelhoch, H., Saroff, H.A., Robbins, J. and Cahnmann, H.J. Negative cooperativity in the binding of thyroxine to human serum prealbumin. Biochemistry 1975, 14(2): 282-9.
25. Costa, P.P., Figueira, A.S. and Bravo, F.R. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A 1978, 75(9): 4499-503.
26. Westermark, P., Sletten, K., Johansson, B. and III Cornwell, G.G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990, 87(8): 2843-5.
27. Sekijima, Y., Wiseman, R.L., Matteson, J. et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005, 121(1): 73-85.
28. Jacobson, D.R., Pastore, R., Pool, S. et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996, 98(2): 236-8.
29. Hornsten, R., Wiklund, U., Olofsson, B.O., Jensen, S.M. and Suhr, O.B. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation 2004, 78(1): 112-6.
30. Coelho, T., Carvalho, M., Saraiva, M.J., Alves, I., Almeida, M.R. and Costa, P.P. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met 30 and TTR Met 119. J Rheumatol 1993, 20: 179.
31. Coelho, T., Chorao, R., Sausa, A., Alves, I., Torres, M.F. and Saraiva, M.J. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscular Disord 1996, 6: 27.
32. Hammarstrom, P., Wiseman, R.L., Powers, E.T. and Kelly, J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299(5607): 713-6.
33. Hammarstrom, P., Schneider, F. and Kelly, J.W. Trans-suppression of misfolding in an amyloid disease. Science 2001, 293(5539): 2459-62.
34. Cardoso, I., Goldsbury C.S., Muller, S.A. et al. Transthyretin fibrillogenesis entails the assembly of monomers: A molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 2002, 317(5): 683-95.
35. Sebastiao, M.P., Lamzin, V., Saraiva, M.J. and Damas, A.M. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J Mol Biol 2001, 306(4): 733-44.
36. Hamilton, J.A. and Benson, M.D. Transthyretin: A review from a structural perspective. Cell Mol Life Sci 2001, 58(10): 1491-521.
37. Wolf, G. Retinol transport and metabolism in transthyretin "knockout" mice. Nutr Rev 1995, 53(4 Pt.1): 98-9.
38. Schreiber, G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol 2002, 175(1): 61-73.
39. Miroy, G.J., Lai, Z., Lashuel, H.A., Peterson, S.A., Strang, C. and Kelly, J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A 1996, 93(26): 15051-6.
40. Wojtczak, A., Cody, V., Luft, J.R. and Pangborn, W. Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3′,5′-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. Acta Crystallogr D Biol Crystallogr 1996, 52(Pt.4): 758-65.
41. Klabunde, T., Petrassi, H.M., Oza, V.B., Raman, P., Kelly, J.W. and Sacchettini, J.C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000, 7(4): 312-21.
42. Adamski-Werner, S.L., Palaninathan, S.K., Sacchettini, J.C. and Kelly, J.W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 2004, 47(2): 355-74.
43. Baures, P.W., Peterson, S.A. and Kelly, J.W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem 1998, 6(8): 1389-401.
44. Almeida, M.R., Gales, L., Damas, A.M., Cardoso, I. and Saraiva, M.J. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 2005, 4(5): 587-96.
45. Johnson, S.M., Wiseman, R.L., Sekijima, Y., Green, N.S., Adamski-Werner, S.L. and Kelly, J.W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on transthyretin amyloidoses. Acc Chem Res 2005, 38(12): 911-21.
46. Johnson, S.M., Petrassi, H.M., Palaninathan, S.K. et al. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem 2005, 48(5): 1576-87.
47. Petrassi, H.M., Johnson, S.M., Purkey, H. et al. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidagenesis: Kinetic stabilization of the native state. J Am Chem Soc 2005, 127: 6662-71.
48. Petrassi, H.M., Klabunde, T., Sacchettini, J.C. and Kelly, J.W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J Am Chem Soc 2000, 122:2178-92.
49. Oza, V.B., Petrassi, H.M., Purkey, H.E. and Kelly, J.W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg Med Chem Lett 1999, 9(1): 1-6.
50. Purkey, H.E., Palaninathan, S.K., Kent, K.C., Smith, C., Safe, S.H., Sacchettini, J.C. and Kelly, J.W. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: Rationalizing rodent PCB toxicity. Chem Biol 2004, 11(12): 1719-28.
51. Foss, T.R., Kelker, M.S., Wiseman, R.L., Wilson, I.A. and Kelly, J.W. Kinetic stabilization of the native state by protein engineering: Implications for inhibition of transthyretin amyloidogenesis. J Mol Biol 2005, 347(4): 841-54.
52. Wiseman, R.L., Johnson, S.M., Kelker, M.S., Foss, T., Wilson, I.A. and Kelly, J.W. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc 2005, 127(15): 5540-51.
53. Miller, S.R., Sekijima, Y. and Kelly, J.W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004, 84(5): 545-52.
54. Tojo, K., Sekijima, Y., Kelly, J.W. and Ikeda, S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2007, 56(4): 441-9.
55. Sekijima, Y., Dendle, M.A. and Kelly, J.W. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006, 13(4): 236-49.
56. Almeida, M.R., Macedo, B., Cardoso, I. et al. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J 2004, 381(Pt. 2): 351-6.
57. Marnett, L.J., Rowlinson, S.W., Goodwin, D.C., Kalgutkar, A.S. and Lanzo, C.A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999, 274(33): 22903-6.
58. Green, G.A. Understanding NSAIDs: From aspirin to COX-2. Clin Cornerstone 2001, 3(5): 50-60.
59. Mukherjee, D., Nissen, S.E. and Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286(8): 954-9.
60. Grimes, R.N. Carboranes. Academic Press: New York 1970.
61. Armstrong, A.F. and Valliant, J.F. The bioinorganic and medicinal chemistry of carboranes: From new drug discovery to molecular imaging and therapy. Dalton Trans 2007, 10(38): 4240-51.
62. Cígler, P., Kožísek, M. Řezácová, P. et al. From nonpeptide to noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease. Proc Natl Acad Sci U S A 2005, 102(43): 15394-9.
63. Debnath, A.K., Jiang, S.B., Strick, N., Lin, K., Kahl, S.B. and Neurath, A.R. Anti-HIV-1 activity of carborane derivatives of porphyrins. Med Chem Res 1999, 9: 267-75.
64. Nachman, R.J., Teal, P.E.T., Radel, P.A., Holman, G.M. and Abernathy, R.L. Potent pheremonotropic/myotropic activity of a carboranyl psuedotetrapeptide analog of the insect pyrokinin/PBAN neuropeptide family administered via injection or topical application. Peptides 1996, 17(5): 747-52.
65. Page, M.F.Z., Jalisatgi, S.S., Maderna, A. and Hawthorne, M.F. Design and synthesis of a candidate alpha-human thrombin irreversible inhibitor containing a hydrophobic carborane pharmacophore. Synthesis 2008, 4: 555-63.
66. Valliant, J.F., Schaffer, P., Stephenson, K.A. and Britten, J.F. Synthesis of boroxifen, a nido-carborane analog of tamoxifen. J Org Chem 2002, 67(2): 383-7.
67. Tsuji, M., Koiso, Y., Takahashi, H., Hashimoto, Y. and Endo, Y. Modulators of tumor necrosis factor production bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. Biol Pharm Bull 2000, 23(4): 513-6.
68. Reynolds, R.C., Campbell, S.R., Fairchild, R.G. et al. Novel boron-containing, nonclassical antifolates: Synthesis and preliminary biological and structural evaluation. J Med Chem 2007, 50(14): 3283-9.
69. Endo, Y., Iijima, T., Yamakoshi, Y., Yamaguchi, M., Fukasawa, H. and Shudo, K. Potent estrogenic agonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. J Med Chem 1999, 42(9): 1501-4.
70. Ohta, K., Iijima, T., Kawachi, E., Kagechika, H. and Endo, Y. Novel retinoid X receptor (RXR) antagonists having a dicarba-closo-dodecaborane as a hydrophobic moiety. Bioorg Med Chem Lett 2004, 14(23): 5913-8.
71. Yamamoto, K. and Endo, Y. Utility of boron clusters for drug design. Hansch-Fujita hydrophobic parameters pi of dicarba-closo-dodecaboranyl groups. Bioorg Med Chem Lett 2001, 11(17): 2389-2392.
72. Julius, R.L., Farha, O.K., Chiang, J., Perry, L.J. and Hawthorne, M.F. Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores. Proc Natl Acad Sci U S A 2007, 104(12): 4808-13.
73. Johnson, S.M., Connelly, S., Wilson, I.A. and Kelly, J.W. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem 2008, 51(2): 260-70.